Swedish Orphan Biovitrum AB (SOBI) NPV

Sell:313.40 SEKBuy:313.80 SEK3.40 SEK (1.08%)

Prices delayed by at least 15 minutes
Sell:313.40 SEK
Buy:313.80 SEK
Change:3.40 SEK (1.08%)
Deal now
Prices delayed by at least 15 minutes
Sell:313.40 SEK
Buy:313.80 SEK
Change:3.40 SEK (1.08%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Swedish Orphan Biovitrum AB (publ) is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.

Key people

David Meek
Chairman of the Board
Henrik Stenqvist
Chief Financial Officer
Christine Wesstroem
Head - Technical Operations
Torbjoern Hallberg
General Counsel and Head of Legal Affairs
Lydia Adab-franch
Chief Medical Officer, Head of Research & Development
Duane H. Barnes
Head of North America
Lena Bjurner
Head of Human Resources
Sofiane Fahmy
Head of Europe
Mahmood Ladha
Head of Strategic Transformation Operations
Norbert Oppitz
Head of International
Mats Lek
Director, Employee Representative
Katy Mazibuko
Director, Employee Representative
Zlatko Rihter
Director
Helena Saxon
Director
Filippa Stenberg
Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Sweden
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    SE0000872095
  • Market cap
    SEK 112.42bn
  • Employees
    1,840
  • Shares in issue
    356.00m
  • Exchange
    Stockholm Stock Exchange
  • Index
    SX All Share PI Market Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.